All In Biotech

Free tool

FAERS Monitor: Depen

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019854 or its brand name (Depen, Penicillamine). Reports on generic versions are filed under their own applications.

Reports

742

Serious

599

81% of reports

Hospitalization

206

Death reported

70

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug hypersensitivity177
  • drug ineffective169
  • arthralgia150
  • joint swelling142
  • inflammation111
  • diarrhoea88
  • nausea87
  • hypersensitivity79
  • drug intolerance78
  • anaphylactic reaction77
  • headache76
  • urticaria71
  • off label use70
  • treatment failure69
  • acute kidney injury68

Reports by year received

View as table
YearReports
200429
200522
20069
200715
200817
200921
201021
201123
201212
20138
201414
201516
201628
201746
201858
201974
2020104
202165
202242
202340
202429
202535
202614

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,417 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
inflammationSignal11161.151.56,504
anaphylactic reactionSignal7739.632.02,859
joint swellingSignal14233.428.84,449
drug hypersensitivitySignal17725.922.84,256
treatment failureSignal6923.618.91,477
drug intoleranceSignal7822.918.61,618
acute kidney injurySignal6812.610.0720
hypersensitivitySignal7912.19.8798
urticariaSignal7112.09.6712
arthralgiaSignal15010.28.91,264
diarrhoeaSignal883.93.2190
drug ineffectiveSignal1693.63.2342
headacheSignal763.42.8133
nauseaSignal873.12.6128
off label useSignal702.31.850

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.